What is the EJS ACT-PD initiative?

We are aiming to revolutionise clinical trials in Parkinson’s disease, by developing a multi-arm, multi-stage platform to accelerate our search for a cure. Currently, there is a gap between each phase of clinical trial, which adds significant delays. Each time a new trial starts, its infrastructure has to be rebuilt from scratch. With Parkinson’s being the fastest growing neurological condition in the world, we need a more efficient way to find answers.

EJS ACT-PD is a patient-driven project which brings together a range of experts, passionate about advancing the delivery of effective Parkinson’s treatments. Our innovative trial platform will simultaneously assess multiple treatments, all designed to slow disease progression. This ground-breaking approach intends to address the challenges in Parkinson’s research and deliver much-needed results, faster.

Project Overview

The EJS ACT-PD Consortium is comprised of 6 Working Groups, an overarching Steering Group and an International Advisory Group. Whilst each Working Group is focused on a specific element of the project, they work collaboratively to reach consensus on all decisions made.